{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Adenocarcinoma+of+the+Colon+or+Rectum&page=7",
    "query": {
      "condition": "Advanced Adenocarcinoma of the Colon or Rectum",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 269,
    "total_pages": 27,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Adenocarcinoma+of+the+Colon+or+Rectum&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Adenocarcinoma+of+the+Colon+or+Rectum&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T19:13:08.900Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06704724",
      "title": "A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Pancreatic Ductal",
        "Colorectal Neoplasms",
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "interventions": [
        {
          "name": "PF-07985045",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cetuximab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Fluorouracil",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Oxaliplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Leucovorin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Bevacizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Pembrolizumab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Sasanlimab",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "pemetrexed",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Cisplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Paclitaxel",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "Carboplatin",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "PF-07284892",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-12-10",
      "completion_date": "2026-05-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-10-14T19:13:08.900Z",
      "location_count": 12,
      "location_summary": "Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 6 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06704724"
    },
    {
      "nct_id": "NCT06305247",
      "title": "A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma",
        "Head and Neck Squamous Cell Carcinoma",
        "Pancreatic Ductal Adenocarcinoma",
        "Colorectal Cancer",
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "IPN01194",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ipsen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2024-04-03",
      "completion_date": "2028-03-20",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-10-14T19:13:08.900Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • San Diego, California • New Haven, Connecticut + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06305247"
    },
    {
      "nct_id": "NCT03872947",
      "title": "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Colorectal Cancer",
        "Cholangiocarcinoma",
        "Bladder Cancer",
        "Ovarian Cancer",
        "Gastric Cancer",
        "Palpable Subcutaneous Malignant Lesions",
        "Renal Cell Carcinoma",
        "Melanoma",
        "Epithelial Ovarian Cancer",
        "Primary Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "TRK-950",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Ramucirumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Imiquimod Cream",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "PLD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Toray Industries, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 138,
      "start_date": "2019-04-26",
      "completion_date": "2026-07-16",
      "has_results": false,
      "last_update_posted_date": "2026-10-08",
      "last_synced_at": "2026-10-14T19:13:08.900Z",
      "location_count": 13,
      "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport",
          "state": "California"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03872947"
    },
    {
      "nct_id": "NCT00026299",
      "title": "Oxaliplatin With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "ZD1839",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2001-09",
      "completion_date": "2005-02",
      "has_results": false,
      "last_update_posted_date": "2013-09-05",
      "last_synced_at": "2026-10-14T19:13:08.900Z",
      "location_count": 12,
      "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 8 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Decatur",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        },
        {
          "city": "Harvey",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00026299"
    },
    {
      "nct_id": "NCT06917079",
      "title": "BBO-11818 in Adult Subjects With KRAS Mutant Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "NSCLC",
        "PDAC - Pancreatic Ductal Adenocarcinoma",
        "CRC (Colorectal Cancer)",
        "Metastatic Non-Small Lung Cell Cancer",
        "Metastatic Colorectal Cancer (CRC)",
        "KRAS G12A",
        "KRAS G12C",
        "KRAS G12D",
        "KRAS G12S",
        "KRAS G12V",
        "Metastatic Pancreatic Ductal Adenocarcinoma",
        "Advanced Lung Carcinoma",
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "BBO-11818",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Platinum chemotherapy (cisplatin or carboplatin)",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX6",
          "type": "DRUG"
        },
        {
          "name": "BBO-10203",
          "type": "DRUG"
        },
        {
          "name": "mFOLFIRINOX",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 665,
      "start_date": "2025-03-31",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2026-06-02",
      "last_synced_at": "2026-10-14T19:13:08.900Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 12 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06917079"
    },
    {
      "nct_id": "NCT03875313",
      "title": "Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor",
        "Clear Cell Renal Cell Carcinoma",
        "TNBC - Triple-Negative Breast Cancer",
        "Colorectal Cancer",
        "CRC",
        "RCC",
        "ccRCC"
      ],
      "interventions": [
        {
          "name": "CB-839",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Calithera Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2019-05-20",
      "completion_date": "2020-07-29",
      "has_results": true,
      "last_update_posted_date": "2022-02-17",
      "last_synced_at": "2026-10-14T19:13:08.900Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03875313"
    },
    {
      "nct_id": "NCT04704661",
      "title": "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Breast Carcinoma",
        "Advanced Colon Carcinoma",
        "Advanced Colorectal Carcinoma",
        "Advanced Endometrial Carcinoma",
        "Advanced Gastric Carcinoma",
        "Advanced Gastroesophageal Junction Adenocarcinoma",
        "Advanced Malignant Solid Neoplasm",
        "Advanced Salivary Gland Carcinoma",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Anatomic Stage IV Breast Cancer AJCC v8",
        "Clinical Stage III Gastric Cancer AJCC v8",
        "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IV Gastric Cancer AJCC v8",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "HER2-Positive Breast Carcinoma",
        "Malignant Hepatobiliary Neoplasm",
        "Metastatic Breast Carcinoma",
        "Metastatic Colon Carcinoma",
        "Metastatic Colorectal Carcinoma",
        "Metastatic Endometrial Carcinoma",
        "Metastatic Gastric Carcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Salivary Gland Carcinoma",
        "Stage III Colon Cancer AJCC v8",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage III Major Salivary Gland Cancer AJCC v8",
        "Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Stage IV Colon Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IV Major Salivary Gland Cancer AJCC v8",
        "Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8",
        "Unresectable Breast Carcinoma",
        "Unresectable Colon Carcinoma",
        "Unresectable Colorectal Carcinoma",
        "Unresectable Endometrial Carcinoma",
        "Unresectable Gastric Carcinoma",
        "Unresectable Gastroesophageal Junction Adenocarcinoma",
        "Unresectable Malignant Solid Neoplasm",
        "Unresectable Salivary Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Ceralasertib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2021-08-09",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-10-14T19:13:08.900Z",
      "location_count": 23,
      "location_summary": "Irvine, California • Los Angeles, California • Orange, California + 16 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04704661"
    },
    {
      "nct_id": "NCT00030524",
      "title": "ZD 1839 in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "gefitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2002-01",
      "completion_date": "2003-09",
      "has_results": false,
      "last_update_posted_date": "2012-10-30",
      "last_synced_at": "2026-10-14T19:13:08.900Z",
      "location_count": 2,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00030524"
    },
    {
      "nct_id": "NCT05500508",
      "title": "Oral AMXT 1501 Dicaprate in Combination With IV DFMO",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cancer",
        "Solid Tumor",
        "Solid Carcinoma",
        "Advanced Cancer",
        "DIPG Brain Tumor",
        "Ovary Cancer",
        "Breast Cancer",
        "Papillary Thyroid Cancer",
        "Head and Neck Cancer",
        "Gastric Cancer",
        "Nsclc",
        "Mesotheliomas Pleural",
        "Mesothelioma Peritoneum",
        "Esophageal Cancer",
        "Diffuse Midline Glioma, H3 K27M-Mutant",
        "Endometrial Cancer",
        "Cervical Cancer",
        "Melanoma",
        "Colorectal Cancer",
        "Glioma, Malignant"
      ],
      "interventions": [
        {
          "name": "AMXT1501",
          "type": "DRUG"
        },
        {
          "name": "DFMO",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aminex Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2022-11-29",
      "completion_date": "2024-12-12",
      "has_results": false,
      "last_update_posted_date": "2024-12-24",
      "last_synced_at": "2026-10-14T19:13:08.900Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05500508"
    },
    {
      "nct_id": "NCT04682431",
      "title": "A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "Gynecologic Cancer",
        "Breast Cancer",
        "Colorectal Cancer",
        "Gastric Adenocarcinoma",
        "Lung Adenocarcinoma",
        "Pancreatic Cancer",
        "Head and Neck Cancer"
      ],
      "interventions": [
        {
          "name": "PY159 Single agent dose level 1",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 2",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 3",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 4",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 5",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 6",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose level 7",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose level 1",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose level 2",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose level 3",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose level 4",
          "type": "DRUG"
        },
        {
          "name": "PY159 Single agent dose expansion cohort",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 1",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 2",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 3",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 4",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 5",
          "type": "DRUG"
        },
        {
          "name": "PY159/Pembrolizumab Combination dose expansion cohort 6",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ikena Oncology",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 127,
      "start_date": "2020-11-10",
      "completion_date": "2023-08-31",
      "has_results": false,
      "last_update_posted_date": "2024-03-22",
      "last_synced_at": "2026-10-14T19:13:08.900Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • San Francisco, California • Santa Monica, California + 14 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04682431"
    }
  ]
}